N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide(2S)-hydroxybutanedioateskype:edisonxu0907MF：C22H27FN4O2.***H6O5MW：532.566CAS：341031-54-7Appearance:redpowderMeltingpoint:189℃~191℃Lossondrying:≤1.0%Totalimpurities:≤1.0%Content:99%Packaging:1kgaluminumfoilbagoraccordingtocustomerrequirementsPurpose:Sunitinibmalatebyblockingtumorcellgrowthtogetbloodandnutrientsneededtoplayatherapeuticrole.ClinicaltrialsshowthatthedrugcanslowthegrowthrateofgastrointestinalstromaltumorsandrenalcelltumorscanbereducedSize.Sunitinibmalateisthefirstnovelcanbeselectivelytargeteddrugsagainstavarietyoftyrosinekinasereceptors,combinedwiththesuspensionofbloodsupplytothetumorcellanti-angiogenicanddirectanti-tumorattacktumorcellsTwomechani***s.Itrepresentstheadventofanewroundoftargetedtherapies,bothdirectlyattackthetumor,norconventionalchemotherapytoxicity.Sunitinibmalateindicati***areasfollows:1,imatinibmesylatebetweenfailureorintolerantgastrointestinalstromaltumors(GIST).2,inoperableadvancedrenalcellcarcinoma(RCC).3,advancedpancreaticendocrinetumors.)